Climb Bio (CLYM) Competitors $1.48 0.00 (0.00%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. GOSS, CYRX, ETON, HUMA, CMPS, ATXS, AURA, ARCT, GLUE, and RNACShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Gossamer Bio (GOSS), CryoPort (CYRX), Eton Pharmaceuticals (ETON), Humacyte (HUMA), COMPASS Pathways (CMPS), Astria Therapeutics (ATXS), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Gossamer Bio CryoPort Eton Pharmaceuticals Humacyte COMPASS Pathways Astria Therapeutics Aura Biosciences Arcturus Therapeutics Monte Rosa Therapeutics Cartesian Therapeutics Gossamer Bio (NASDAQ:GOSS) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment. Is GOSS or CLYM more profitable? Climb Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -41.12%. Climb Bio's return on equity of -43.95% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-41.12% -128.98% -15.52% Climb Bio N/A -43.95%-42.94% Does the media favor GOSS or CLYM? In the previous week, Gossamer Bio and Gossamer Bio both had 1 articles in the media. Gossamer Bio's average media sentiment score of 0.00 equaled Climb Bio'saverage media sentiment score. Company Overall Sentiment Gossamer Bio Neutral Climb Bio Neutral Which has more volatility & risk, GOSS or CLYM? Gossamer Bio has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Do analysts recommend GOSS or CLYM? Gossamer Bio currently has a consensus price target of $8.25, suggesting a potential upside of 363.48%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 508.11%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Climb Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders have more ownership in GOSS or CLYM? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 6.7% of Gossamer Bio shares are held by insiders. Comparatively, 0.8% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, GOSS or CLYM? Gossamer Bio has higher revenue and earnings than Climb Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M3.53-$56.53M-$0.23-7.74Climb BioN/AN/A-$73.90M-$2.38-0.62 SummaryGossamer Bio beats Climb Bio on 8 of the 14 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.01M$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-0.6220.7327.9019.95Price / SalesN/A321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book0.478.308.635.90Net Income-$73.90M-$55.19M$3.24B$258.42M7 Day Performance1.37%5.07%3.22%1.94%1 Month Performance14.73%17.61%10.72%12.02%1 Year PerformanceN/A7.03%34.94%20.81% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.614 of 5 stars$1.48flat$9.00+508.1%N/A$100.01MN/A-0.629GOSSGossamer Bio3.5284 of 5 stars$1.71+3.0%$8.25+382.5%+74.8%$377.32M$114.70M-7.43180Gap UpHigh Trading VolumeCYRXCryoPort2.0844 of 5 stars$7.43-0.3%$10.88+46.4%-13.5%$373.52M$228.38M-3.181,186Positive NewsAnalyst UpgradeInsider TradeAnalyst RevisionETONEton Pharmaceuticals2.4704 of 5 stars$13.95+0.4%$29.67+112.7%+330.7%$372.50M$39.01M-77.5020Analyst RevisionHUMAHumacyte1.7259 of 5 stars$2.42+1.3%$11.71+384.1%-67.1%$370.73M$1.57M-3.51150News CoverageAnalyst ForecastCMPSCOMPASS Pathways2.0146 of 5 stars$3.88-1.3%$17.00+338.1%-36.5%$367.70MN/A-1.95120Upcoming EarningsATXSAstria Therapeutics1.3171 of 5 stars$6.24-1.4%$30.00+380.8%-42.7%$357.23MN/A-3.3430AURAAura Biosciences2.7194 of 5 stars$7.12+2.4%$22.00+209.0%-25.8%$349.37MN/A-3.7550Positive NewsARCTArcturus Therapeutics1.7881 of 5 stars$13.54+5.4%$54.00+298.8%-34.6%$348.50M$152.31M-5.35180GLUEMonte Rosa Therapeutics2.1094 of 5 stars$5.90+5.2%$15.33+159.9%+30.7%$345.07M$75.62M73.7690News CoverageRNACCartesian Therapeutics1.6943 of 5 stars$12.53-5.6%$40.00+219.2%-21.3%$344.41M$38.91M-0.2464News Coverage Related Companies and Tools Related Companies Gossamer Bio Competitors CryoPort Competitors Eton Pharmaceuticals Competitors Humacyte Competitors COMPASS Pathways Competitors Astria Therapeutics Competitors Aura Biosciences Competitors Arcturus Therapeutics Competitors Monte Rosa Therapeutics Competitors Cartesian Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLYM Stock Alerts